247 related articles for article (PubMed ID: 18241249)
1. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
Liu H; Schwartz MJ; Hwang DH; Scherr DS
BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
Smith EB; Schwartz M; Kawamoto H; You X; Hwang D; Liu H; Scherr DS
J Urol; 2007 Jun; 177(6):2347-51. PubMed ID: 17509356
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
5. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
6. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells.
Zou C; Liebert M; Zou C; Grossman HB; Lotan R
J Urol; 2001 Mar; 165(3):986-92. PubMed ID: 11176527
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
8. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
9. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
Konety BR; Lavelle JP; Pirtskalaishvili G; Dhir R; Meyers SA; Nguyen TS; Hershberger P; Shurin MR; Johnson CS; Trump DL; Zeidel ML; Getzenberg RH
J Urol; 2001 Jan; 165(1):253-8. PubMed ID: 11125420
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
11. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer.
Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
BJU Int; 2008 Jan; 101(1):106-12. PubMed ID: 17941929
[TBL] [Abstract][Full Text] [Related]
12. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
Duggan BJ; Maxwell P; Kelly JD; Canning P; Anderson NH; Keane PF; Johnston SR; Williamson KE
J Urol; 2001 Sep; 166(3):1098-105. PubMed ID: 11490306
[TBL] [Abstract][Full Text] [Related]
13. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.
Wu MJ; Chang CH; Chiu YT; Wen MC; Shu KH; Li JR; Chiu KY; Chen YT
Urol Oncol; 2012; 30(1):69-77. PubMed ID: 20207175
[TBL] [Abstract][Full Text] [Related]
14. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
[TBL] [Abstract][Full Text] [Related]
15. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of the aqueous extract of Magnolia officinalis on the responses of human urinary bladder cancer 5637 cells in vitro and mouse urinary bladder tumors induced by N-Butyl-N-(4-hydroxybutyl) nitrosamine in vivo.
Lee SJ; Cho YH; Park K; Kim EJ; Kang BS; Jung KH; Kim CH; Kim WJ; Moon SK
Phytother Res; 2009 Jan; 23(1):20-7. PubMed ID: 19048611
[TBL] [Abstract][Full Text] [Related]
17. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.
Hadaschik BA; Jackson J; Fazli L; Zoubeidi A; Burt HM; Gleave ME; So AI
BJU Int; 2008 Aug; 102(5):610-6. PubMed ID: 18384625
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines.
Nishikawa T; Kohjimoto Y; Nishihata M; Ebisuno S; Hara I
Urology; 2009 Dec; 74(6):1370-6. PubMed ID: 19428092
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor is a potential therapeutic target for bladder cancer.
Wu JT; Han BM; Yu SQ; Wang HP; Xia SJ
Urology; 2010 Apr; 75(4):820-7. PubMed ID: 20083299
[TBL] [Abstract][Full Text] [Related]
20. NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation.
Smakman N; Schaap N; Snijckers CM; Borel Rinkes IH; Kranenburg O
Urology; 2005 Aug; 66(2):434-40. PubMed ID: 16098373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]